{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:30:25Z","timestamp":1794807025622,"version":"4.9.1"},"reference-count":196,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.eururo.2025.02.019","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T08:12:07Z","timestamp":1742458327000},"page":"582-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":277,"title":["European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines"],"prefix":"10.1016","volume":"87","author":[{"given":"Antoine G.","family":"van der Heijden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harman Max","family":"Bruins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Carrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Dimitropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"Kailavasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Param","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Panebianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e6bj\u00f8rn","family":"S\u00e6bj\u00f8rnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.02.019_b0005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.02.019_b0010","unstructured":"International Agency for Research on Cancer. Estimated number of new cases in 2020, worldwide, both sexes, all ages. International Agency for Research on Cancer, World Health Organization."},{"key":"10.1016\/j.eururo.2025.02.019_b0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2011.03.047","article-title":"Trends in mortality from urologic cancers in Europe, 1970\u20132008","volume":"60","author":"Bosetti","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.02.019_b0030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ije\/dyw044","article-title":"Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies","volume":"45","author":"van Osch","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.eururo.2025.02.019_b0035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice","volume":"20","author":"van Hoogstraten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/oem.2009.050195","article-title":"Bladder cancer among hairdressers: a meta-analysis","volume":"67","author":"Harling","year":"2010","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0045","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1080\/15287390801988681","article-title":"N-acetyltransferase-2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany","volume":"71","author":"Weistenhofer","year":"2008","journal-title":"J Toxicol Environ Health A"},{"key":"10.1016\/j.eururo.2025.02.019_b0050","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijrobp.2011.08.034","article-title":"Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer","volume":"83","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.02.019_b0055","unstructured":"U.S. Food & Drug Administration. FDA Drug Safety Podcast 2016: Updated FDA review concludes that use of pioglitazone may be linked to an increased risk of bladder cancer."},{"key":"10.1016\/j.eururo.2025.02.019_b0060","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00345-018-2257-z","article-title":"Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis","volume":"36","author":"Bayne","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.euf.2019.06.001","article-title":"Sex-specific differences in the quality of treatment of muscle-invasive bladder cancer do not explain the overall survival discrepancy","volume":"7","author":"Krimphove","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.019_b0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2018.03.001","article-title":"Bladder cancer survival: Women better off in the long run","volume":"95","author":"Andreassen","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2025.02.019_b0075","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ejca.2010.10.007","article-title":"Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis","volume":"47","author":"Dietrich","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2025.02.019_b0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.23986","article-title":"Sex and racial differences in bladder cancer presentation and mortality in the US","volume":"115","author":"Scosyrev","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.02.019_b0085","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2010.01.030","article-title":"Words of wisdom. Re: sex and racial differences in bladder cancer presentation and mortality in the US","volume":"57","author":"Stenzl","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ije\/dyz264","article-title":"The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses' Health Study and Nurses' Health Study II","volume":"49","author":"Abufaraj","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.eururo.2025.02.019_b0095","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41379-019-0403-9","article-title":"Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"33","author":"Varma","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2025.02.019_b0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.eururo.2012.07.026","article-title":"Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis","volume":"64","author":"Fajkovic","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.eururo.2012.09.053","article-title":"Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma","volume":"63","author":"Fritsche","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0110","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euo.2019.09.003","volume":"2","author":"Veskimae","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0115","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.02.019_b0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2025.02.019_b0125","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/sj.bjc.6605637","article-title":"Occupation and cancer in Britain","volume":"102","author":"Rushton","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2025.02.019_b0130","unstructured":"World Health Organization, International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:1\u2013241."},{"key":"10.1016\/j.eururo.2025.02.019_b0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.urolonc.2009.12.020","article-title":"Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy","volume":"30","author":"Ploeg","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00428-009-0849-0","article-title":"Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage","volume":"455","author":"Varinot","year":"2009","journal-title":"Virchows Arch"},{"key":"10.1016\/j.eururo.2025.02.019_b0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2009.03.010","article-title":"Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer","volume":"74","author":"Mazzucchelli","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.019_b0150","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.eururo.2007.07.031","article-title":"Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy","volume":"53","author":"Pettus","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0155","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/2051415815617876","article-title":"Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy","volume":"9","author":"von Rundstedt","year":"2016","journal-title":"J Clin Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.06.014","article-title":"Accuracy of urethral frozen section during radical cystectomy for bladder cancer","volume":"34","author":"Kates","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0165","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.juro.2018.04.065","article-title":"Can renal and bladder ultrasound replace computerized tomography urogram in patients investigated for microscopic hematuria?","volume":"200","author":"Tan","year":"2018","journal-title":"J Urol"},{"issue":"545\u201355","key":"10.1016\/j.eururo.2025.02.019_b0170","first-page":"vii","article-title":"MR imaging of the bladder","volume":"12","author":"Mallampati","year":"2004","journal-title":"Magn Reson Imaging Clin North Am"},{"key":"10.1016\/j.eururo.2025.02.019_b0175","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.crad.2011.05.019","article-title":"Bladder cancer: evaluation of staging accuracy using dynamic MRI","volume":"66","author":"Rajesh","year":"2011","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2025.02.019_b0180","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bju.16191","article-title":"Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"133","author":"Necchi","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.019_b0185","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eururo.2019.09.029","article-title":"Prospective assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its clinical impact on the management of high-risk non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection","volume":"77","author":"Del Giudice","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0195","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1007\/s00330-021-07765-5","article-title":"The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study","volume":"31","author":"Metwally","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2025.02.019_b0200","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41585-023-00830-2","article-title":"Clinical application of bladder MRI and the Vesical Imaging-Reporting and Data System","volume":"21","author":"Panebianco","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0205","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1007\/s00330-022-08813-4","article-title":"Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field","volume":"32","author":"Watanabe","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2025.02.019_b0210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1148\/radiology.193.1.8090898","article-title":"Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging","volume":"193","author":"Kim","year":"1994","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2025.02.019_b0215","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1464-410X.2007.06766.x","article-title":"Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour","volume":"99","author":"Cowan","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.eururo.2025.02.019_b0220","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.juro.2009.12.031","article-title":"Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy","volume":"183","author":"Takahashi","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0225","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1007\/s003300050916","article-title":"MR imaging of the male pelvis","volume":"9","author":"Barentsz","year":"1999","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2025.02.019_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2022.01.002","article-title":"Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: a multicenter cohort from the European Association of Urology - Young Academic Urologists","volume":"40","author":"Lonati","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0235","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.euf.2017.06.005","article-title":"Detection of lymph node metastasis in patients with bladder cancer using maximum standardised uptake value and (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography: results from a high-volume centre including long-term follow-up","volume":"5","author":"Vind-Kezunovic","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.019_b0240","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2022.09.017","article-title":"Positron emission tomography\/computed tomography for staging of bladder cancer: a continuing clinical controversy","volume":"83","author":"Mertens","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0245","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2214\/AJR.07.3472","article-title":"Pulmonary nodules: detection, assessment, and CAD","volume":"191","author":"Girvin","year":"2008","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2025.02.019_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000318985","article-title":"Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society","volume":"85","author":"Heidenreich","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2025.02.019_b0255","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euo.2021.01.005","article-title":"Staging (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography changes treatment recommendation in invasive bladder cancer","volume":"5","author":"Voskuilen","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0260","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.euo.2020.06.004","article-title":"The value of multiparametric magnetic resonance imaging sequences to assist in the decision making of muscle-invasive bladder cancer","volume":"4","author":"Bandini","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.09.035","article-title":"[18F]Fluoro-deoxy-glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab","volume":"39","author":"Marandino","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0270","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00261-021-03365-5","article-title":"Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report","volume":"47","author":"Pecoraro","year":"2022","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eururo.2025.02.019_b0275","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.euf.2021.05.005","article-title":"Role of radiomics in the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Kozikowski","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.019_b0280","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2967\/jnumed.124.267474","article-title":"Role of (64)CuCl(2) PET\/CT in detecting and staging muscle-invasive bladder cancer: comparison with contrast-enhanced CT and (18)F-FDG PET\/CT","volume":"65","author":"Piccardo","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0285","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s00259-024-06595-z","article-title":"[(68 )Ga]Ga-FAPI-46 PET\/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis","volume":"51","author":"Unterrainer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.02.019_b0290","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3322\/caac.21406","article-title":"Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology","volume":"67","author":"Ethun","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2025.02.019_b0295","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.euf.2017.08.005","article-title":"Comparative perioperative outcomes in septuagenarians and octogenarians undergoing radical cystectomy for bladder cancer\u2014do outcomes differ?","volume":"4","author":"Haden","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.019_b0300","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcsm.12279","article-title":"Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer","volume":"9","author":"Mayr","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.eururo.2025.02.019_b0305","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.eururo.2010.02.024","article-title":"Prevention and management of complications following radical cystectomy for bladder cancer","volume":"57","author":"Lawrentschuk","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0310","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.juro.2013.12.041","article-title":"Risk factors for the development of parastomal hernia after radical cystectomy","volume":"191","author":"Donahue","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0315","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bju.12240","article-title":"The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer","volume":"113","author":"Djaladat","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.eururo.2025.02.019_b0320","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bju.12405","article-title":"Preoperative serum albumin is associated with mortality and complications after radical cystectomy","volume":"113","author":"Garg","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.019_b0325","doi-asserted-by":"crossref","first-page":"E222","DOI":"10.1111\/j.1464-410X.2012.10938.x","article-title":"Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder","volume":"110","author":"Mayr","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.eururo.2025.02.019_b0330","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.juro.2011.04.089","article-title":"Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy","volume":"186","author":"Morgan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0335","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1245\/s10434-011-1852-7","article-title":"Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study","volume":"19","author":"Abdollah","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0340","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/cncr.23462","article-title":"Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer","volume":"112","author":"Koppie","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.02.019_b0345","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/j.1464-410X.2010.09417.x","article-title":"Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival","volume":"106","author":"Bolenz","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.019_b0350","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4111\/kju.2011.52.7.446","article-title":"Does radical cystectomy improve overall survival in octogenarians with muscle-invasive bladder cancer?","volume":"52","author":"Yoo","year":"2011","journal-title":"Korean J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0355","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2407-4-94","article-title":"An electronic application for rapidly calculating Charlson comorbidity score","volume":"4","author":"Hall","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2025.02.019_b0360","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.bjc.6601231","article-title":"Performance status score: do patients and their oncologists agree?","volume":"89","author":"Blagden","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2025.02.019_b0365","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1200\/JCO.1995.13.9.2272","article-title":"Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial","volume":"13","author":"Logothetis","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0370","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0375","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.eururo.2011.07.063","article-title":"German Association of Urological Oncology Bladder Cancer Group. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20\/99)","volume":"60","author":"Niegisch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.06.009","article-title":"Effect of tumor location on survival in urinary bladder adenocarcinoma: a population-based analysis","volume":"34","author":"Dutta","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0385","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.juro.2018.05.162","article-title":"Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: a systematic review and meta-analysis","volume":"201","author":"Kimura","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0390","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.urology.2014.05.011","article-title":"Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy","volume":"84","author":"Svatek","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.019_b0395","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0022-5347(05)66441-5","article-title":"Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance","volume":"165","author":"Donat","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0400","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/PAP.0000000000000152","article-title":"Challenges in pathologic staging of bladder cancer: proposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances","volume":"24","author":"Paner","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.eururo.2025.02.019_b0405","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/BLC-160086","article-title":"Impact of the level of urothelial carcinoma involvement of the prostate on survival after radical cystectomy","volume":"3","author":"Moschini","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2025.02.019_b0410","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0415","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2025.02.019_b0420","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0425","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2025.02.019_b0430","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0435","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.02.019_b0440","unstructured":"ClinicalTrials\/gov. A study of atezolizumab versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer who are ctDNA positive following cystectomy (IMvigor011). NCT04660344. Clinical Trials Web site. https:\/\/clinicaltrials.gov\/study\/NCT04660344."},{"key":"10.1016\/j.eururo.2025.02.019_b0445","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0450","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00345-006-0061-7","article-title":"Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure","volume":"24","author":"Stein","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0455","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0022-5347(05)66440-3","article-title":"Cystectomy for bladder cancer: a contemporary series","volume":"165","author":"Dalbagni","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0460","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.juro.2007.03.101","article-title":"Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base","volume":"178","author":"David","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0465","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urolonc.2009.03.021","article-title":"Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer","volume":"29","author":"Porter","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0470","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(05)64047-5","article-title":"An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma","volume":"169","author":"Sanchez-Ortiz","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0475","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0022-5347(05)64048-7","article-title":"Contemporary concepts of radical cystectomy and the treatment of bladder cancer","volume":"169","author":"Stein","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0480","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2018.09.004","article-title":"Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes","volume":"2","author":"Boeri","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0485","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2025.02.019_b0490","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0495","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/cncr.30907","article-title":"Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology","volume":"123","author":"Vetterlein","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.02.019_b0500","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0505","first-page":"1931","article-title":"Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis","volume":"18","author":"Huncharek","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2025.02.019_b0510","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.urolonc.2019.05.021","article-title":"The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: a systematic review","volume":"37","author":"Iwata","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0515","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ijrobp.2024.05.012","article-title":"The value and safety of adjuvant radiation therapy after radical cystectomy in locally advanced urothelial bladder cancer: a controlled randomized study","volume":"120","author":"Zaghloul","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.02.019_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.04.013","article-title":"Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: a systematic review","volume":"35","author":"Hernandez","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0525","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1442-2042.2012.03148.x","article-title":"Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy","volume":"20","author":"Simone","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0530","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","article-title":"Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial","volume":"75","author":"Gschwend","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0535","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa2401497","article-title":"Standard or extended lymphadenectomy for muscle-invasive bladder cancer","volume":"391","author":"Lerner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0540","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2023.04.004","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy: a systematic review and meta-analysis of perioperative, oncological, and quality of life outcomes using randomized controlled trials","volume":"84","author":"Khetrapal","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0545","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.eururo.2020.12.023","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in bladder cancer patients: a multicentre comparative effectiveness study","volume":"79","author":"Wijburg","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0550","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1590\/s1677-5538.ibju.2020.0892","article-title":"Bricker ileal conduit vs. Cutaneous ureterostomy after radical cystectomy for bladder cancer: a systematic review","volume":"48","author":"Korkes","year":"2022","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0555","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.urology.2022.08.020","article-title":"Ileal conduit versus continent urinary diversion in radical cystectomy: a retrospective cohort study of 30-day complications, readmissions, and mortality","volume":"170","author":"Rezaee","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.019_b0560","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.urolonc.2021.06.009","article-title":"Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: a systematic review and meta-analysis","volume":"39","author":"Laukhtina","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0565","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/JU.0000000000000034","article-title":"Positive pre-cystectomy biopsies of the prostatic urethra or bladder neck do not necessarily preclude orthotopic bladder substitution","volume":"201","author":"Roth","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0570","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/JU.0000000000000512","article-title":"Decision regret related to urinary diversion choice among patients treated with cystectomy","volume":"203","author":"Check","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0575","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2020.06.039","article-title":"Reporting radical cystectomy outcomes following implementation of enhanced recovery after surgery protocols: a systematic review and individual patient data meta-analysis","volume":"78","author":"Williams","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0580","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.juro.2015.05.083","article-title":"Postoperative pain management after radical cystectomy: comparing traditional versus enhanced recovery protocol pathway","volume":"194","author":"Xu","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0585","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1245\/s10434-011-1723-2","article-title":"Rates of venous thromboembolism among patients with major surgery for cancer","volume":"18","author":"Hammond","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0590","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2340\/sju.v59.40120","article-title":"Cystectomy for bladder cancer in Sweden\u2014short-term outcomes after centralization","volume":"59","author":"Liedberg","year":"2024","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0595","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0360-3016(00)00430-2","article-title":"A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09","volume":"47","author":"Duchesne","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.02.019_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.11.042","article-title":"Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer","volume":"39","author":"Maisch","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0605","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.euo.2020.02.007","article-title":"Diagnostic performance of Vesical Imaging Reporting and Data System for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"3","author":"Woo","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0610","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0615","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13566-017-0319-2","article-title":"Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation","volume":"6","author":"Korpics","year":"2017","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0620","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijrobp.2017.01.239","article-title":"Clinical outcomes of image guided adaptive hypofractionated weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment","volume":"98","author":"Hafeez","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.02.019_b0625","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.23.02718","article-title":"Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: an inverse probability treatment weighted analysis","volume":"43","author":"Marcq","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0630","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis","volume":"7","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0635","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0640","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0645","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712\u2014a randomized phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109584","article-title":"Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study","volume":"183","author":"de Haar-Holleman","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0655","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euo.2023.05.013","article-title":"Long-term outcomes of chemoradiation for muscle-invasive bladder cancer in noncystectomy candidates. final results of NRG Oncology RTOG 0524\u2014a phase 1\/2 trial of paclitaxel + trastuzumab with daily radiation or paclitaxel alone with daily irradiation","volume":"7","author":"Dahl","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0660","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0665","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0670","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0675","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0680","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0685","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0690","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","article-title":"Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-preserving therapy: a nationwide study","volume":"118","author":"Bruck","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.02.019_b0695","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.juro.2017.08.106","article-title":"Incidence, clinicopathological risk factors, management and outcomes of nonmuscle invasive recurrence after complete response to trimodality therapy for muscle invasive bladder cancer","volume":"199","author":"Sanchez","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0700","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0705","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JU.0000000000004160","article-title":"The impact of histologic subtypes on clinical outcomes after radiation-based therapy for muscle-invasive bladder cancer","volume":"212","author":"Halstuch","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0710","first-page":"38","article-title":"A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database. Clin Transl","volume":"15","author":"Fischer-Valuck","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0715","first-page":"30","article-title":"Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: an analysis of the National Cancer Database","volume":"26","author":"Janopaul-Naylor","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0720","unstructured":"Advanced Bladder Cancer Meta-analysis Collaborators Group. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials. Eur Urol 2022; 81: 50\u201361."},{"key":"10.1016\/j.eururo.2025.02.019_b0725","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0730","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","author":"Apolo","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0735","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0740","unstructured":"U.S. Food & Drug Administration. FDA approves nivolumab for adjuvant treatment of urothelial carcinoma."},{"key":"10.1016\/j.eururo.2025.02.019_b0745","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0750","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0755","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0760","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.21.00286","article-title":"Randomized phase III trial of gemcitabine and cisplatin with bevacizumab or placebo in patients with advanced urothelial carcinoma: results of CALGB 90601 (Alliance)","volume":"39","author":"Rosenberg","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0765","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0770","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0775","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0780","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after >\/=2 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0785","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0790","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0795","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2025.02.019_b0800","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0805","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.02.019_b0810","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0815","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0820","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/onco.13925","article-title":"Efficacy of platinum rechallenge in metastatic urothelial carcinoma after previous platinum-based chemotherapy for metastatic disease","volume":"26","author":"Wong","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2025.02.019_b0825","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdq398","article-title":"Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20\/99]","volume":"22","author":"Albers","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0830","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1742-1241.2005.00663.x","article-title":"German Association Of Urologic Oncology Bladder Cancer Study Group. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20\/99)","volume":"60","author":"Fechner","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2025.02.019_b0835","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0840","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0140-6736(17)32365-6","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial","volume":"390","author":"Petrylak","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.02.019_b0845","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(19)30668-0","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial","volume":"21","author":"Petrylak","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0850","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0855","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.02.019_b0860","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0865","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.019_b0870","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 Long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0875","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0880","doi-asserted-by":"crossref","unstructured":"Powles T, Tagawa S, Vulsteke C, et al. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol. In press. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.011.","DOI":"10.1016\/j.annonc.2025.01.011"},{"key":"10.1016\/j.eururo.2025.02.019_b0885","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.eururo.2023.05.005","article-title":"Definition and diagnosis of oligometastatic bladder cancer: a Delphi consensus study endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty","volume":"84","author":"Bamias","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0890","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2016.66.7352","article-title":"Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: a propensity score-weighted analysis from the National Cancer Data Base","volume":"34","author":"Seisen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0895","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.euo.2022.02.001","article-title":"Association between local radiation therapy to the primary bladder tumor and overall survival for patients with metastatic urothelial cancer receiving systemic chemotherapy","volume":"5","author":"Fischer-Valuck","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0900","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.eururo.2008.11.039","article-title":"Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30\/05)","volume":"55","author":"Lehmann","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0905","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0910","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3390\/cancers15041161","article-title":"Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis","volume":"15","author":"Aboudaram","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2025.02.019_b0915","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.3390\/cancers15072069","article-title":"Retrospective analysis of a cohort of patients with metastatic bladder cancer with metastatic sites limited to the pelvis and retroperitoneum treated at a single institution between 2009 and 2020","volume":"15","author":"Bertucci","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2025.02.019_b0920","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.3390\/cancers16183201","article-title":"Oligometastatic urothelial cancer and stereotactic body radiotherapy: a systematic review and an updated insight of current evidence and future directions","volume":"16","author":"Angrisani","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2025.02.019_b0925","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","article-title":"A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer","volume":"25","author":"Yang","year":"2016","journal-title":"Surg Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110038","article-title":"Quality of life after definitive treatment for bladder cancer: a systematic review and meta-analysis","volume":"190","author":"Francolini","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.02.019_b0935","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.02.019_b0940","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41585-022-00693-z","article-title":"Health-related quality of life after curative treatment for muscle-invasive bladder cancer","volume":"20","author":"Grobet-Jeandin","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0945","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2006.10.040","article-title":"Muscle-invasive urothelial carcinoma of the bladder","volume":"69","author":"Malkowicz","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.019_b0950","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.juro.2012.08.017","article-title":"Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients","volume":"188","author":"Picozzi","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0955","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","article-title":"Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature","volume":"62","author":"Soukup","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0960","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.juro.2008.03.024","article-title":"Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later","volume":"180","author":"Ghoneim","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0965","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/01.ju.0000051462.45388.14","article-title":"Long-term outcome of ileal conduit diversion","volume":"169","author":"Madersbacher","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.019_b0970","unstructured":"Brierley JD GM, Wittekind C. TNM classification of malignant tumors. ed. 8. UICC International Union Against Cancer. Oxford, MA: Wiley-Blackwell and UICC; 2016."},{"key":"10.1016\/j.eururo.2025.02.019_b0975","unstructured":"Gontero P, Comp\u00e9rat EM. EAU guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). Presented at the 40th EAU Annual Congress Madrid 2025. 2025."},{"key":"10.1016\/j.eururo.2025.02.019_b0980","unstructured":"Neuzillet Y, Witjes J, Comp\u00e9rat E. EAU guidelines on primary urethral carcinoma. Presented at the 40th EAU Annual Congress Madrid 2025. 2025."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T13:32:25Z","timestamp":1744637545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825001381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":196,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0302283825001381"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.02.019","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}